… genital warts within a large US commercially insured, geographically dispersed population.
… Genital warts cases were identified using a methodology previously described by Insinga et …

… associated with treating genital warts in the USA among a commercially insured population.
… -year costs associated with treating genital warts in the USA among a commercially insured …

… diagnoses from a diagnosis of condyloma acuminata, or either a less specific viral wart
diagnosis or genital wart medication combined with either a benign anogenital neoplasm or …

… care and reducing population-level costs. This study is limited by its restriction to a commercially
insured population and an inability to assess relative effectiveness of wart treatments. …

… According to our definitions, we identified a total of 39 493 people with 43 586 episodes
of genital warts from 1998 to 2006. The majority of these patients were identified from the …

… of the HPV vaccine. We identified genital warts with an algorithm combining genital wart–…
We defined a genital wart recurrence as a diagnosis of genital warts that occurred at least 6 …

… We also thank GPRD for providing the data on genital warts in general practice for this
study and all the practices that contribute to the GPRD. We are grateful to Julia Stowe and the …

… We assessed temporal trend in the incidence and prevalence of genital warts (GWs) in the
province of Quebec, Canada, between 1998 and 2007 as a baseline for future assessment of …

… . Assessing incidence and economic burden of genital warts with data from a US
commercially insured population. Curr Med Res Opin 2009;25:2343–51.doi:10.1185/…

… This study provides the first quantification of the economic burden of treating genital warts
in Peru and one of the few in Latin America. The costing data did not include other healthcare …